Complete Long Term Remission of an Advanced Progressive Osteoclastoma of the Sacrum through the Immunobiological Issels Treatment without further Standard Treatment.
P. N. -F., Born 1935, File 125/67
4 years survival, tumor not palpable, well being, no recurrence, patient working as a sociologist and author.
TREATMENT HISTORY First Diagnosis | Standard Treatment | Issels Treatment
April 1957
Diagnosis: Sacral tumor. Histology: Giant cell tumor (osteoclastoma) Grade II. Westminster Hospital London/England.
Treatment: Megavolt radiation therapy.
Result: Considerable improvement.
Standard/ Conventional Treatment
February 1961
Local and Abdominal First Recurrence.
Treatment: Chemotherapy.
No remission.
June 1961
Progression of tumor growth.
Treatment: Other combination of chemotherapy.
Partial remission. Stop of growth.
April 1964.
April 1964
Renewed progressive growth of residual disease.
Findings: Enormous hard, rock-like mass extending from sacrum forward, filling the pelvis, bilateral hydro-ureters, fecal incontinence, paralysis of sacral nerve roots. (Westminster Hospital, London/England) Partial resection. Patient refuses removal of sacrum.
Histology: Osteoclastoma Grade II.
January 1967
Renewed bilateral urethral obstruction by the tumor, bilateral obstruction of kidneys, danger of uraemia.
No Standard Treatment. Patient refuses removal of sacrum.
February 1967
Admission exam: 10 cm wide tumor with two knots in the left hypogastrium (lower abdomen) adherent to the posterior pelvic wall. Urea significantly increased.
February to June 1967
Issels Treatment: 18 weeks of immunobiological in-patient treatment with 6 months of out-patient follow-up treatment.
Discharge exam: Tumor has decreased in size, freedom of pain, urea normal, well-being.
Follow-up
until 1971
4 years survival, tumor not palpable, well being, no recurrence, patient working as a sociologist and author.
>>> For ADDITIONAL INFORMATION on treatment and costs please click here or CALL 1.888.447.7357.
>>> To read the ISSELS TREATMENT SUMMARY, please click here for details.